Gujarat Themis Biosyn Limited (BOM:506879)

Market Cap	44.03B +50.1%
Revenue (ttm)	1.66B +10.0%
Net Income	466.82M -4.3%
EPS	4.28 -4.4%
Shares Out	108.97M
PE Ratio	94.42
Forward PE	n/a
Dividend	0.67 (0.17%)
Ex-Dividend Date	Sep 4, 2025

Volume	35,333
Open	429.95
Previous Close	433.50
Day's Range	400.50 - 429.95
52-Week Range	225.75 - 479.45
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	May 25, 2026

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 221
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506879

Financial Performance

In fiscal year 2026, Gujarat Themis Biosyn's revenue was 1.66 billion, an increase of 9.96% compared to the previous year's 1.51 billion. Earnings were 466.82 million, a decrease of -4.29%.